Separate Phakic IOL Trials Recommended For Young, Old Patients
This article was originally published in The Gray Sheet
Executive Summary
Refractive implant manufacturers pursuing claims for device implantation in phakic eyes - those with a natural lens - should conduct separate studies on younger and older patient populations to examine the risk of cataractogenesis, FDA's Ophthalmic Devices Advisory Panel recommended at a May 12 meeting.
You may also be interested in...
Intraocular Lens Postmarket Surveillance Supported By Ophthalmic Panelists
Postmarket surveillance for phakic intraocular lenses (IOLs) is largely favored by members of FDA's Ophthalmic Devices Panel, although recommended duration could vary depending on risk
Intraocular Lens Postmarket Surveillance Supported By Ophthalmic Panelists
Postmarket surveillance for phakic intraocular lenses (IOLs) is largely favored by members of FDA's Ophthalmic Devices Panel, although recommended duration could vary depending on risk
IOL Myopia, Hyperopia Studies Should Include 3-Year Follow Up - FDA Panel
Intraocular lens manufacturers pursuing approval for myopia and hyperopia indications should conduct 550-patient studies with three-year follow up, FDA's Ophthalmic Devices Advisory Panel concluded at an Oct. 23 meeting in Silver Spring, Maryland.